About LogicBio TherapeuticsA preclinical-stage company with a mission to develop cures for life-threatening diseases, LogicBio combines the best of gene therapy and genome-editing technology. Founded by gene-therapy pioneers from leading academic institutions including Stanford University, Tel Aviv University, and Children’s Medical Research Institute in Sydney – the company’s core platform includes its proprietary GeneRide technology and synthetic gene-therapy vectors derived from naturally occurring human adeno-associated viruses. LogicBio designed its approach to harness the natural power of homologous recombination - enabling precise, site-specific transfer of the genetic material without the use of promoters or nucleases, which could be associated with unwanted side effects. The goal: provide patients with a functional version of a faulty, disease-causing gene to deliver a cure. LogicBio is advancing programs for rare, life-threatening pediatric genetic diseases - focusing first on inborn errors of metabolism, where there are few, if any, treatment options. A number of the company’s discoveries have been featured in leading science publications and conferences. A private company, LogicBio is based in Cambridge, Massachusetts, with a research group in Tel Aviv.
Founders: Adi Barzel Ph.D., Mark Kay M.D. Ph.D. and Leszek Lisowski Ph.D.
President & CEO: Frederic Chereau
75 articles with LogicBio Therapeutics
New leadership includes Andrea Paul as general counsel and corporate secretary, and Janice Olson as senior vice president, strategy and portfolio management, bringing extensive experience in gene therapy and rare disease
LogicBio Announces Presentations at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood, today announced several preclinical data presentations, including an oral presentation, will be delivered at the 24th Annual American Society of Gene and Cell Therapy (ASGCT) Virtual Meeting
LogicBio Announces Presentation of Retrospective Study of Disease Course in Pediatric Patients with Severe Methylmalonic Acidemia
LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood, today announced results from a retrospective study of the disease course in pediatric patients living with severe methylmalonic acidemia
LogicBio Therapeutics Announces Strategic Collaboration and Option Agreement with CANbridge Pharmaceuticals Leveraging Gene Editing and Gene Delivery Platforms
- LogicBio grants exclusive option to license LB-001 in Greater China; investigational treatment for methylmalonic acidemia based on GeneRide™ platform - Deal also grants worldwide license for AAV sL65, the first capsid based on LogicBio proprietary sAAVyTM platform, to support development of CANbridge gene therapy programs for Fabry disease, Pompe disease and options for two additional indications
- Under the terms of the research collaboration and exclusive option agreement, the companies will initiate a gene editing research program dedicated to the treatment of two early onset indications with high unmet need, leveraging the GeneRide™ platform -
- First patient for Phase I/II SUNRISE trial expected to be enrolled by mid-year 2021 - Company also entered into strategic collaboration with CANbridge Pharmaceuticals and research partnership with Daiichi Sankyo
CANbridge Pharmaceuticals Announces Strategic Collaboration with LogicBio Therapeutics and Licenses to Gene Delivery and Editing Platforms
Worldwide License to AAV sL65 Capsid, Novel Liver-Targeting Capsid, to Support Development of CANbridge Gene Therapy Programs for Fabry disease, Pompe disease and Options for two Additional Indications Option to Exclusive License for LB-001, Investigational Gene Editing Treatment for Methylmalonic Acidemia, in Greater China
LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood, today announced that chief executive officer Frederic Chereau will be participating on a panel at the 2021 Redburn Gene Therapy Summit.
- First patient for Phase 1/2 SUNRISE trial expected to be enrolled in early 2021 -Translational preclinical data for sAAVy platform shows substantial improvements over liver tropic capsids used in gene therapy programs to date -New Chief Scientific and Chief Financial Officers recently added to Executive Team
Collaboration seeks to develop next-generation viral vectors for gene therapy and gene editing applications in liver and two other tissues. Program brings new levels of momentum to LogicBio as company plans for initiation of enrollment of SUNRISE Phase I/II clinical trial in treatment of methylmalonic acidemia (MMA) and other milestones.
LogicBio Therapeutics, Inc. (Nasdaq: LOGC), a clinical stage genetic medicines company, today announced that president and chief executive officer Fred Chereau will present virtually at the 39 th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021 at 4:30 pm ET . Mr. Chereau will provide an overview of com
LogicBio Therapeutics, Inc. (Nasdaq: LOGC), a clinical stage genetic medicines company, today announced the appointment of Cecilia Jones as the Company's chief financial officer, effective January 11, 2021.
12/18/2020Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
LogicBio Therapeutics, Inc. (Nasdaq: LOGC), a clinical stage genetic medicines company developing therapies based on advanced gene editing technology and next-generation synthetic capsids, today announced that Daphne Karydas and Jeff Goater have been appointed to the Company's board of directors.
LogicBio Therapeutics, Inc., a company dedicated to extending the reach of genetic medicine with pioneering targeted delivery announced senior member of management will be presenting at upcoming investor conferences
IND for LB-001 in methylmalonic acidemia (MMA)cleared in August 2020, with first patient in Phase 1/2 SUNRISE trial expected to be enrolled in early 2021
LogicBio Therapeutics Receives FDA Fast Track Designation for LB-001 for the Treatment of Methylmalonic Acidemia (MMA)
LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio), a company dedicated to extending the reach of genetic medicine with pioneering targeted delivery platforms, announced today the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its clinical candidate, LB-001 for the treatment methylmalonic acidemia (MMA). According to the FDA, the purpose of Fast Track designation is to get important new drugs to patients earli
While the world has largely been focused on the development of vaccines and therapeutics for COVID-19, the U.S. FDA has remained busy lining up potential approvals of medications for other diseases and illnesses.
LogicBio Therapeutics Announces Appointment of Veteran Biotech Executive Mariana Nacht, Ph.D., as Chief Scientific Officer and Kyle Chiang, Ph.D., Promoted to Chief Operating Officer
LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio), a company dedicated to extending the reach of genetic medicine with pioneering targeted delivery platforms, today announced the appointment of Mariana Nacht, Ph.D., as chief scientific officer, effective Nov. 30, 2020, and the promotion of Kyle Chiang, Ph.D., to chief operating officer, effective Nov. 2, 2020.
LogicBio Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio), a company dedicated to extending the reach of genetic medicine with pioneering targeted delivery platforms, today announced the closing of its previously announced underwritten public offering of 8,050,000 shares of common stock at a price to the public of $6.00 per share, which includes the exercise in full of the underwriters’ option to purchase additional shares of common stock. The gro